Advances in Population Pharmacokinetic Studies of Polymyxin B in Critically Ill Patients
Multidrug-resistant bacteria in the intensive care unit are complex and refractory,leading to prolonged hospitalisation and increased morbidity and mortality,and polymyxin B serves as one of the last options for multidrug-resistant Gram-negative bacteria.The sig-nificant inter-and intra-individual pharmacokinetic differences exhibited by patients with severe infections pose a great challenge to anti-infec-tive therapy.This article provides an overview of the pharmacological effects of polymyxin B,pharmacokinetics,pharmacodynamics,and progress in population pharmacokinetic studies in critically ill patients,with a view to providing ideas for rational clinical use of the drug.
万方数据
维普
